Seminars in Nephrology
Volume 27, Issue 5 , Pages 555-564 , September 2007

Should β-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?

  • Peter D. Hart, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Cook County Hospital, Chicago, IL.
    • ,
  • George L. Bakris, MD

      Affiliations

    • Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago–Pritzker School of Medicine, Chicago, IL.
    • Corresponding Author InformationAddress reprint requests to George L. Bakris, MD, Department of Medicine, University of Chicago School of Medicine, 5841 S. Maryland St, MC 1027, Chicago, IL 60637.

References 

  1. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: finding from the third national Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207–1216
  2. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1–S290
  3. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906
  4. Antman EM, Anbe DT, Armstrong PW, et al. A guideline for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2004;110:588–636
  5. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003;16:7S–12S
  6. Salomonsson M, Brannstrom K, Arendshorst WJ. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol. 2000;278:F138–F147
  7. Epstein M, Oster JR, Hollenberg NK. b-blockers and the kidney: implications for renal function and renin release. Physiologist. 1985;28:53–63
  8. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41:621–624
  9. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002;4:256–260
  10. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722–727
  11. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878–882
  12. Ye S, Zhong H, Yanamadala V, et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002;15:717–724
  13. Salplachta J, Bartosikova L, Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys. 2002;21:189–195
  14. Amann K, Nichols C, Tornig J, et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant. 1996;11:1003–1011
  15. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427–2433
  16. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321–1328
  17. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918
  18. Klein IHHT, Lightenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239–3244
  19. Neumann J, Lightenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease is reduced during standard treatment. Hypertension. 2007;49:506–510
  20. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–1979
  21. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–1359
  22. Orth SR, Amann K, Strojek K, et al. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant. 2001;16:S67–S69
  23. Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004;19:1829–1834
  24. Eknoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes. Am J Kidney Dis. 1998;32:S1–S4
  25. Zuanetti G, Maggioni AP, Keane W, et al. Nephrologists neglect administration of beta blockers to dialysed diabetic patients. Nephrol Dial Transplant. 1997;12:2497–2500
  26. Abbott KC, Trespalacios FC, Agodoa LY, et al. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004;164:2465–2471
  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  28. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int. 2002;62:1784–1790
  29. Horl MP, Horl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial. 2004;17:288–294
  30. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444
  31. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002;62:1799–1805
  32. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563–570
  33. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905–1913
  34. Meier J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J. 1982;104:364–373
  35. Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem. 1990;8(Suppl 2):28–34
  36. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41:39–52
  37. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens. 1998;11:1258–1265
  38. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension (A randomized, controlled trial). Ann Intern Med. 1997;126:955–959
  39. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489–494
  40. Williams ME, Gervino EV, Rosa RM, et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985;312:823–827
  41. Arrizabalaga P, Montoliu J, Martinez VA, et al. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc. 1983;20:572–576
  42. Mehrotra S, Ling KL, Bekele Y, et al. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus. Diabet Med. 2001;18:109–115
  43. Onozato ML, Tojo A, Goto A, et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002;61:186–194
  44. Ueno Y, Kizaki M, Nakagiri R, et al. Dietary glutathione protects rats from diabetic nephropathy and neuropathy. J Nutr. 2002;132:897–900
  45. Dupont AG. Carvedilol and the kidney. Clin Invest. 1992;70(Suppl 1):S127–S131
  46. Epstein M, Oster JR. Beta blockers and renal function: a reappraisal. J Clin Hypertens. 1985;1:85–99
  47. Abbott KC, Bakris G. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993;33:392–399
  48. Zech P, Pozet N, Labeeuw M, et al. Acute renal effects of beta-blockers. Am J Nephrol. 1986;6(Suppl 2):15–19
  49. Sugino G, Barg AP, O’Connor DT. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis. 1984;3:357–361
  50. Dreslinski GR, Messerli FH, Dunn FG, et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. Circulation. 1982;65:1365–1368
  51. Yasumoto R, Asakawa M, Kakinoki K, et al. [Effect of metoprolol in patients with renal hypertension.]. Hinyokika Kiyo. 1988;34:1669–1673
  52. van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993;45:509–517
  53. Malini PL, Strocchi E, Negroni S, et al. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol. 1982;13:123S–126S
  54. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens. 1985;1:171–178
  55. Keusch G, Weidmann P, Ziegler WH, et al. Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. Klin Wochenschr. 1980;58:25–29
  56. Cruz F, O’Neill WM, Clifton G, et al. Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther. 1981;30:57–63
  57. Rasmussen S, Nielsen PE. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol. 1981;12:349–353
  58. Dupont AG, Van der NP, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S130–S136
  59. Calo LA, Semplicini A, Davis PA. Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med. 2005;118:201–202
  60. Tomita K, Makumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S97–S101
  61. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646–661
  62. UKPD Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 (UK Prospective Diabetes Study Group). BMJ. 1998;317:713–720
  63. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ. 1987;294:1443–1447
  64. Cook ME, Wallin JD, Clifton GG, et al. Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity. Clin Pharmacol Ther. 1988;43:393–399
  65. Kohno M, Takeda T, Ishii M, et al. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension (An open, short term study. Carvedilol Renal Hypertension Study Group in Japan). Drugs. 1988;36(Suppl 6):129–135
  66. Takeda T, Kohno M, Ishii M, et al. Efficacy and safety of carvedilol in renal hypertension (A multicenter open trial). Eur J Clin Pharmacol. 1990;38(Suppl 2):S158–S163
  67. Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339–343
  68. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833–837
  69. Lacourciere Y, Nadeau A, Poirier L, et al. Captopril or conventional therapy in hypertensive type II diabetics (Three-year analysis). Hypertension. 1993;21:786–794
  70. Apperloo AJ, de Zeeuw D, Sluiter HE, et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ. 1991;303:821–824
  71. Himmelmann A, Hansson L, Hansson BG, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press. 1995;4:85–90
  72. Wright JT, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease (Results from the AASK trial). JAMA. 2002;288:2421–2431
  73. Seiler KU, Schuster KJ, Meyer GJ, et al. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5:192–198
  74. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int. 1999;55:1528–1535
  75. Branten AJ, Hilbrands LB, van Hamersvelt HW, et al. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant. 1998;13:423–426
  76. Kirch W, Kohler H, Mutschler E, et al. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol. 1981;19:65–71
  77. Jordo L, Attman PO, Aurell M, et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5:169–180
  78. Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int. 2003;16:313–320
  79. Hara Y, Hamada M, Shigematsu Y, et al. Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond). 2001;101:219–225
  80. McCauley J, Murray J, Jordan M, et al. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002;22:347–351
  81. Hamad A, Salameh M, Zihlif M, et al. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol. 2001;21:241–244
  82. Gehr TW, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999;55:269–277
  83. Miki S, Masumura H, Kaifu Y, et al. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol. 1991;18(Suppl 4):S62–S68
  84. Masumura H, Miki S, Kaifu Y, et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S102–S107
  85. Deetjen A, Heidland A, Pangerl A, et al. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol. 1995;43:47–52
  86. Nowicki M, Szewczyk-Seifert G, Klimek D, et al. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol. 2002;57:352–358
  87. Calo L, Giacon B, Davis PA, et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension (Effect of carvedilol and nifedipine). Clin Nephrol. 2002;58:103–110
  88. Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant. 1997;11:577–581
  89. Leeman M, Vereerstraeten P, Uytdenhoef M, et al. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol. 1993;22:706–710
  90. Rahman M, Smith MC. Chronic renal insufficiency: a diagnostic and therapeutic approach. Arch Intern Med. 1998;158:1743–1752
  91. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884–890
  92. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12:212–221
  93. Agrawal B, Wolf K, Berger A, et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens. 1996;10:551–555
  94. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract. 1999;53:519–522
  95. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236
  96. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46:1309–1315
  97. Giner V, Tormos C, Chaves FJ, et al. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med. 2004;255:588–594
  98. Raats CJ, Bakker MA, van den BJ, et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem. 1997;272:26734–26741

PII: S0270-9295(07)00088-5

doi: 10.1016/j.semnephrol.2007.07.003

Seminars in Nephrology
Volume 27, Issue 5 , Pages 555-564 , September 2007

Article Tools